%0 Journal Article
%A Katz, Deborah A
%A Morris, Joan D
%A Chu, Michael P
%A David, Kevin A
%A Thieblemont, Catherine
%A Morley, Nicholas J
%A Khan, Sharif S
%A Viardot, Andreas
%A Martín García-Sancho, Alejandro
%A Rodríguez-García, Guillermo
%A Bastos-Oreiro, Mariana
%A Lee, Seung Tae
%A Kormany, William
%A Chen, Yuqi
%A Wong, Hansen L
%A Anderson, Abraham A
%A Katlinskaya, Yuliya
%A Avilion, Ariel A
%A Dai, Tian
%A González-Barca, Eva
%T Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL.
%D 2022
%U http://hdl.handle.net/10668/19676
%X This open-label, multicenter, single-arm, phase 2 study assessed the safety and efficacy of blinatumomab consolidation therapy in adult patients with newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL; International Prognostic Index 3-5 and/or double-/triple-hit or double MYC/BCL-2 expressors) who achieved complete response (CR), partial response (PR), or stable disease (SD) following run-in with 6 cycles of R-chemotherapy (NCT03023878). Of the 47 patients enrolled, 28 received blinatumomab. Five patients (17.9%) experienced grade 4 treatment-emergent adverse events of interest (neutropenia, n = 4; infection, n = 1). Two deaths reported at the end of the study were unrelated to treatment with blinatumomab (disease progression, n = 1; infection, n = 1). 3/4 patients with PR and 4/4 patients with SD after R-chemotherapy achieved CR following blinatumomab. Consolidation with blinatumomab in patients with newly diagnosed, high-risk DLBCL who did not progress under R-chemotherapy was better tolerated than in previous studies where blinatumomab was used for treatment of patients with lymphoma.
%K Relapsed/refractory
%K blinatumomab
%K high-risk DLBCL
%~